ClinicalTrials.gg
Active, not recruitingNCT03440450Updated Sep 2, 2026

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

A Phase 1 interventional study of FF-10832 Gemcitabine Liposome Injection in Advanced Solid Tumors and Biliary Tract Cancer, sponsored by Fujifilm Pharmaceuticals U.S.A., Inc.. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Fujifilm Pharmaceuticals U.S.A., Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.

Enrollment
68th of 140
90 · median 75
Started
2018
with 2 others
Phase 1
33 of 155
14 open now
Primary completion
2026-10
later than 10 of 66 live
Registered
56th of 155
by date

Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 68th largest by enrollment of the 140 interventional ones that give a count, is one of 3 that started in 2018, is one of 33 in phase 1, reaches primary completion later than 10 of the 66 other live ones, and was the 56th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Biliary Tract Neoplasms with a site in United States, or all of them as a file.
02

Study summary

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer

Read the detailed description

Dose-escalation Phase:

Eligible patients will receive FF-10832 in 28 day or 21 day cycles. Dosing will continue until progression of disease, observation of unacceptable adverse events, intercurrent illness, or changes in the patient's condition that prevents further study participation after discussion between the Investigator and the Medical Monitor. A number of cohorts will be enrolled sufficient to determine the MTD and to identify the RP2D.

Expansion Phase:

One cohort of biliary tract cancer will enroll up to 18 patients in a 21 day cycle.

03

Conditions studied

  • Advanced Solid Tumors
  • Biliary Tract Cancer

Keywords

  • Liposomal gemcitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 years of age
  2. or cytologically confirmed solid tumor, to standard therapy, or for which no standard therapy is available that is expected to improve survival by at least three months
  3. At least 3 weeks beyond the last chemotherapy (or 3 half-lives, whichever is shorter), radiotherapy, major surgery, or experimental treatment, and recovered from all acute toxicities (≤ Grade 1), prior to the first dose of FF-10832
  4. Cohort expansion phase: (biliary tract cancer):

    • Histologically or cytologically confirmed cholangiocarcinoma or gall bladder carcinoma that is metastatic pancreatic adenocarcinoma following progression or relapseor unresectable
    • by 1.1
    • Progressed on at least one prior regimengemcitabine-cisplatin therapy or gemcitabine-based therapy if unable to tolerate cisplatin. therapy counts as such therapy.
    • Progressed on, declined on, or was ineligible for therapies directed against fibroblast growth factor (FGFR) and/or isocitrate dehydrogenase (IDH) mutations for tumors appropriately treated with such therapies
    • No more than 3 prior systemic therapies for their tumor. Please contact the medical monitor if there are any questions about eligibility.
    • A serum albumin level ≥ 3 g/dL on entry to the study
  5. Adequate performance status: (ECOG) ≤ 1
  6. of ≥ 3 months
  7. Ability to provide written

Exclusion criteria

Exclusion Criteria:

  1. Patients who have not received standard/approved therapies expected to improve survival by at least 3 months
  2. Prior to gemcitabine
  3. Known positive for (HIV), virus surface antigen (HBsAg) or virus (HCV)

7. Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment

8. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results

9. Pregnant or breast-feeding

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Cohort 1: Treatment at 1.2 mg/m2

    FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10832 Gemcitabine Liposome Injection

  • Experimental
    Cohort 2: Treatment at 2.4 mg/m2

    FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10832 Gemcitabine Liposome Injection

  • Experimental
    Cohort 3: Treatment at 4.8 mg/m2

    FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10832 Gemcitabine Liposome Injection

  • Experimental
    Cohort 4: Treatment at 8 mg/m2

    FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10832 Gemcitabine Liposome Injection

  • Experimental
    Expansion Cohort: Treatment at Recommended Phase 2 Dose (RP2D)

    For patients with biliary tract cancer: FF-10832 Gemcitabine Liposome Injection, RP2D administered intravenously (IV) on Day 1 of each 21-day cycle

    Drug: FF-10832 Gemcitabine Liposome Injection

Interventions

  • DrugFF-10832 Gemcitabine Liposome Injection

    FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

    Also known as: FF-10832

06

What researchers measure

Primary outcomes

  1. Determine incidence of Treatment Emergent Adverse Events (TEAE)

    Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 2.5 years

  2. Identify dose-limiting toxicities (DLT) of FF-10832

    DLT is defined as any adverse event at least possibly related to FF-10832, and meeting specified DLT criteria

    Time frame: 2.5 years

  3. Determine maximun tolerated dose (MTD) of FF-10832

    MTD is defined as the next lower dose of a cohort where patients experienced a DLT

    Time frame: 2.5 years

Secondary outcomes

  1. Disease Assessment by CT or MRI scan for solid tumors

    Disease assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1), clinical benefit is defined as best response of complete response (CR), partial response (PR), stable disease (SD) or disease progression (DP)

    Time frame: 2.5 years

  2. Disease Assessment by CT or MRI + PET scan for pancreatic cancer

    For solid tumors assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1), clinical benefit is defined as best response of complete response (CR), partial response (PR), stable disease (SD) or disease progression (DP). European Organisation for Research and Treatment of Cancer (EORTC) criteria will be utilized for PET response assessments.

    Time frame: 2.5 years

  3. Duration of Response

    Duration of Response is calculated from the date of first response to the date of progression or death

    Time frame: 2.5 years

  4. Duration of Stable Disease

    Duration of Stable Disease is the length of time from the start of the treatment until the criteria for progression are met

    Time frame: 2.5 years

  5. Time to progression (TTP)

    Time to progression is calculated from the date of first treatment to the date of first progression

    Time frame: 2.5 years

  6. Progression-free survival (PFS)

    Progression-free survival will be calculated from the date of first treatment to the date of progression or death

    Time frame: 2.5 years

  7. Overall survival (OS)

    Overall survival will be calculated from the date of first treatment to the date of death from any cause; patients who do not experience death will be censored at the last follow-up time.

    Time frame: 2.5 years

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Oct 2026, 103 months after the start.

Of 34 phase 1 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 30. This study's planned 103 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 22, 2018
StartActual
Mar 22, 2018
Primary completionEst.
Oct 2026
CompletionEst.
Mar 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03440450
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Mar 22, 2018
Primary completion
Oct 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion